Lines by EBV Nuclear Antigen-Specific CD4 the Recognition of EBV-Transformed B Cell A Role for Intercellular Antigen Transfer in
暂无分享,去创建一个
[1] A. Moosmann,et al. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins , 2006, The Journal of experimental medicine.
[2] M. Bonneville,et al. Long-Term MHC Class II Presentation of the EBV Lytic Protein BHRF1 by EBV Latently Infected B Cells following Capture of BHRF1 Antigen1 , 2005, The Journal of Immunology.
[3] H. Rammensee,et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] Delu Zhou,et al. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. , 2005, Immunity.
[5] A. Rickinson,et al. CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines , 2005, Journal of Virology.
[6] A. Rickinson,et al. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells , 2005, The Journal of experimental medicine.
[7] T. Tuschl,et al. Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy , 2005, Science.
[8] L. Young,et al. Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.
[9] W. Hammerschmidt,et al. Epstein‐Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells , 2004, European journal of immunology.
[10] B. Rocha,et al. Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. , 2004, Current opinion in immunology.
[11] M. Bonneville,et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. , 2004, Blood.
[12] E. Jaffee,et al. Major histocompatibility complex class II‐restricted presentation of a cytosolic antigen by autophagy , 2003, European journal of immunology.
[13] H. Heslop,et al. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. , 2002, Cancer research.
[14] A. Rickinson,et al. Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2 , 2002, Nature Medicine.
[15] Hiroya Kobayashi,et al. Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope1 , 2002, The Journal of Immunology.
[16] S. Stevanović,et al. Epstein-Barr Nuclear Antigen 1-Specific CD4+ Th1 Cells Kill Burkitt’s Lymphoma Cells1 , 2002, The Journal of Immunology.
[17] D. Crawford,et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. , 2001, Transplantation.
[18] E. Bloemena,et al. Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses , 2001, Journal of Virology.
[19] A. Rudensky,et al. Efficient Presentation of Both Cytosolic and Endogenous Transmembrane Protein Antigens on MHC Class II Is Dependent on Cytoplasmic Proteolysis1 , 2001, The Journal of Immunology.
[20] A. Rickinson,et al. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. , 2001, Cancer research.
[21] S. Riddell,et al. Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells1 , 2001, The Journal of Immunology.
[22] W. Hammerschmidt,et al. The Epstein–Barr virus lytic program is controlled by the co‐operative functions of two transactivators , 2000, The EMBO journal.
[23] R. Steinman,et al. Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1 , 2000, The Journal of experimental medicine.
[24] J. Elliott,et al. Cytoplasmic Processing Is a Prerequisite for Presentation of an Endogenous Antigen by Major Histocompatibility Complex Class II Proteins , 2000, The Journal of experimental medicine.
[25] R. Karr,et al. A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes. , 2000, International immunology.
[26] Richard E. Slaughter,et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Eggermont,et al. Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.
[28] M. Nishioka,et al. Efficient Class II Major Histocompatibility Complex Presentation of Endogenously Synthesized Hepatitis C Virus Core Protein by Epstein-Barr Virus-Transformed B-Lymphoblastoid Cell Lines to CD4+ T Cells , 1998, Journal of Virology.
[29] A. Alcamí,et al. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. , 1998, The Journal of general virology.
[30] D. Srivastava,et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.
[31] L. Frappier,et al. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. , 1997, Immunity.
[32] M. Jackson,et al. Major Histocompatibility Complex Class II-dependent Unfolding, Transport, and Degradation of Endogenous Proteins* , 1997, The Journal of Biological Chemistry.
[33] S. Burrows,et al. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. , 1997, International immunology.
[34] P. Cresswell,et al. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. , 1997, Journal of immunology.
[35] A. Rickinson,et al. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. , 1997, Journal of immunology.
[36] Eric O Long,et al. Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[37] C. Melief,et al. B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.
[38] S. Burrows,et al. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. , 1995, Virology.
[39] Kathleen R. Cho,et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[40] S. Tonegawa,et al. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: On the role of intracellular compartmentalization, invariant chain and the TAP transporter system , 1995, European journal of immunology.
[41] S. Diment,et al. Processing of a viral glycoprotein in the endoplasmic reticulum for class II presentation , 1995, European journal of immunology.
[42] J. Trowsdale,et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein‐Barr virus latent membrane protein‐1: coordinate up‐regulation of peptide transporters and HLA‐class I antigen expression , 1995, European journal of immunology.
[43] S. Burrows,et al. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. , 1994, The Journal of general virology.
[44] S. Burrows,et al. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. , 1994, International immunology.
[45] Eric O Long,et al. Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC. , 1993, Journal of immunology.
[46] A. Rickinson,et al. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide , 1993, The Journal of experimental medicine.
[47] M. Masucci,et al. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4 , 1993, Journal of virology.
[48] E. Kieff,et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies , 1992, The Journal of experimental medicine.
[49] E. Kieff,et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development , 1992, The Journal of experimental medicine.
[50] Eric O Long,et al. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells , 1992, Nature.
[51] S. Weiss,et al. MHC class II—Restricted presentation of intracellular antigen , 1991, Cell.
[52] Eric O Long,et al. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells , 1990, The Journal of experimental medicine.
[53] R. Siliciano,et al. Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition , 1990, The Journal of experimental medicine.
[54] I. Berkower,et al. Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen , 1988, The Journal of experimental medicine.
[55] P. Seglen,et al. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[56] W. Joklik. The purification fo four strains of poxvirus. , 1962, Virology.